The stock of Apollo Endosurgery Inc. (NASDAQ:APEN) last traded at $9.95, unchanged from the previous session.
Data from the available sources indicates that Apollo Endosurgery Inc. (NASDAQ:APEN) is covered by 4 analysts. The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $14.00 and a low of $10.00, we find $10.00. Given the previous closing price of $9.95, this indicates a potential upside of 0.5 percent. APEN stock price is now 0.42% away from the 50-day moving average and 45.69% away from the 200-day moving average. The market capitalization of the company currently stands at $472.62M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
In total, 3 analysts have assigned it a hold rating, and 1 have given it a buy rating. Brokers who have rated the stock have averaged $11.00 as their price target over the next twelve months.
With the price target maintained at $10, Stifel recently Downgraded its rating from Buy to Hold for Apollo Endosurgery Inc. (NASDAQ: APEN). On November 30, 2022, Lake Street Downgraded its previous ‘Buy’ rating to ‘Hold’ on the stock reducing its target price from $14 to quote $10, while ‘Cowen’ rates the stock as ‘Outperform’.
Insiders disposed of 87,803 shares of company stock worth roughly $0.87 million over the past 1 year. A total of 0.80% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in APEN stock. A new stake in Apollo Endosurgery Inc. shares was purchased by JPMORGAN CHASE & CO during the first quarter worth $10,690,000. WOODLINE PARTNERS LP invested $7,590,000 in shares of APEN during the first quarter. In the first quarter, BOONE CAPITAL MANAGEMENT LLC acquired a new stake in Apollo Endosurgery Inc. valued at approximately $7,148,000. BERRY STREET CAPITAL MANAGEMENT LLP acquired a new stake in APEN for approximately $6,219,000. FIRST TRUST CAPITAL MANAGEMENT L.P. purchased a new stake in APEN valued at around $4,723,000 in the second quarter. In total, there are 71 active investors with 74.30% ownership of the company’s stock.
With an opening price of $9.95 on Monday morning, Apollo Endosurgery Inc. (NASDAQ: APEN) set off the trading day. During the past 12 months, Apollo Endosurgery Inc. has had a low of $3.49 and a high of $10.30. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 6.00, and a quick ratio of 5.00. The fifty day moving average price for APEN is $9.91 and a two-hundred day moving average price translates $6.83 for the stock.
The latest earnings results from Apollo Endosurgery Inc. (NASDAQ: APEN) was released for Sep, 2022. According to the Medical Devices Company, earnings per share came in at -$0.28, missing analysts’ expectations of -$0.23 by -0.05. This compares to -$0.23 EPS in the same period last year. The net profit margin was -56.70% and return on equity was -78.70% for APEN. The company reported revenue of $19.57 million for the quarter, compared to $16.35 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 19.71 percent. For the current quarter, analysts expect APEN to generate $19.88M in revenue.
Apollo Endosurgery Inc.(APEN) Company Profile
Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices. The company offers OverStitch and OverStitch Sx Endoscopic Suturing Systems that enable advanced endoscopic procedures by allowing physicians to sutures and secure the approximation of tissue through a flexible endoscope. It also provides Orbera, an intragastric balloon system that reduces stomach capacity causing patients to consume less following the procedure, as well as delays gastric content emptying under the Orbera Intragastric Balloon System, BIB, and Orbera365 Managed Weight Loss System brands. Additionally, the company offers X-Tack Endoscopic HeliX Tacking System, a suture-based device for closing and healing defects in the lower and upper gastrointestinal tract. The company sells its products to medical services providers; and hospitals, outpatient surgical centers, clinics, and physicians in the United States, Australia, Costa Rica, and other European countries. Apollo Endosurgery, Inc. was founded in 2005 and is headquartered in Austin, Texas.
Leave a Reply